MSCs: From clinical trials to clinical practice

Symposium | Quality of life and symptoms in cGvHD

What are the treatment options for ruxolitinib-refractory acute GvHD?

Symposium | Early treatment strategies for SR-GvHD

Symposium | The importance of real-world data in allogeneic cell transplantation: A focus on cGvHD

What are the current treatment options for steroid-refractory chronic GvHD?

What are the major challenges in the treatment of SR-GvHD, and how can clinicians overcome these?

How can measurement of QoL and use of PROs be improved in cGvHD?

ECP + ruxolitinib to prevent cGvHD in patients with SR-aGvHD

Key insights into MSCs for aGvHD – the current clinical trial landscape

Real-world use of belumosudil: Key insights and future perspectives

How does real-world evidence complement RCTs, and why is it important for small patient populations?

cGvHD: Answering the unanswered

How should we be measuring GvHD QoL in clinical practice?

Results from the phase II STARGAZE trial

cGvHD symposium highlights

Management of drug related adverse events in patients with steroid refractory GvHD

Infection prophylaxis for patients with GvHD

Future perspectives of ECP for GvHD treatment

Symposium | Q&A | How ECP can affect lymphocyte count during and after treatment?

Symposium | Early intervention and use of ECP combinations in cGvHD

Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops

Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up

Symposium | The Long-term burden of chronic GvHD

Symposium | Q&A | Value and challenges of ECP in pediatric patients

Symposium: A brief history of ECP

Symposium | Q&A | Impact of ECP on the GvHD treatment landscape

Supportive care provision for patients with GvHD

GvHD prophylaxis: novel strategies and future directions

Is the novel JAK/ROCK inhibitor TQ05105 effective for patients with SR and SD cGvHD?

Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?

What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?

Case study | Therapy-refractory chronic GvHD

How to sequence agents for steroid-refractory chronic GvHD

Is vedolizumab effective for preventing lower GI acute GvHD?

Itacitinib and corticosteroids for chronic GvHD

Key considerations for the use of ECP in GvHD

What is extracorporeal photopheresis?

ECP: Looking to the future

What is the latest update on the GRAVITAS-309 trial?

The role of ECP in the management of GvHD

Does using haplo-HSCT compared with cord blood transplant impact GvHD rates?

What is the role of human beta-defensin-2 in modulation of the microbiome and aGvHD?

How should duration of response be defined?

How should novel agents be used in the current treatment pathways for GvHD?

How to optimize donor selection for allogeneic transplant?

How would you treat aGvHD in your clinic (an EU perspective)?

What is the latest update on biomarkers for assessing GvHD?

What should supportive care look like for patients with GvHD? What role does physical activity pl...

How do we stratify risk in patients with GvHD?

How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?

Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment

When would you use ATG vs PTCy for GvHD prophylaxis?

How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as g...

What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

How can patient-reported QoL change our view on unmet needs in GvHD?

How do pre-allo-HSCT conditioning regimens impact GvHD outcomes in myelofibrosis patients?

How might itacitinib prophylaxis impact haplo-HSCT outcomes in the future?

How is failure-free survival impacted by belumosudil in cGvHD which has failed prior therapy?

How could uhCG/EGF fit into current aGvHD treatment pathways?